Company code: Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) company abbreviation: Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) bond Code: 113585 bond abbreviation: Shouxian convertible bond zhejiangshouxiangu Pharmaceutical Co, Ltd.
(No. 10, Shangcheng Road, Hushan street, Wuyi County, Zhejiang Province)
Annual report for 2021
April 1, 2002
Section I important tips
1 the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should go to www.sse.com com. cn. The website carefully reads the full text of the annual report. 2. The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and completeness of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 3. All directors of the company attend the board meeting. 4. Lixin Certified Public Accountants (special general partnership) issued a standard unqualified audit report for the company. 5. The profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period adopted by the resolution of the board of directors
The company plans to distribute a cash dividend of 4.05 yuan (including tax) to all shareholders for every 10 shares based on the total share capital on the date of profit distribution equity registration in 2021 minus the shares in the special account for repurchase, and increase 3 shares for every 10 shares to all shareholders in the form of capital reserve converted into share capital. If the total share capital of the company changes before the equity registration date of equity distribution, it is proposed to maintain the distribution (conversion) ratio per share unchanged and adjust the total distribution (conversion) accordingly.
Section II basic information of the company
1 company profile
Company stock profile
Stock type stock exchange stock abbreviation stock abbreviation before stock code change
A-share Shanghai Stock Exchange Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) /
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Liu Guofang
Office address: No. 12, Huanglong Third Road, Wuyi County, Zhejiang Province
Tel: 057987622285
E-mail [email protected].
2. Main business profile of the company in the reporting period (1) overview of traditional Chinese medicine decoction pieces industry
In September 2021, the general office of the State Council issued the national medical security plan for the 14th five year plan, which proposed to build an efficient medical service supply system from the three aspects of “optimizing and improving the medical and health service system”, “improving the supply and security capacity of pharmaceutical products” and “strengthening the consultation and co governance mechanism”. In “optimizing and improving the medical and health service system”, it was pointed out that “we should support the inheritance, innovation and development of traditional Chinese medicine, strengthen the role of traditional Chinese medicine in disease prevention and treatment, and promote the intervention scheme of traditional Chinese medicine in treating and preventing diseases.” As one of the major sectors of the pharmaceutical and biological industry, the traditional Chinese medicine sector mainly includes three sub industries: Traditional Chinese medicine, traditional Chinese medicine decoction pieces and traditional Chinese patent medicine. Among them, decoction pieces of traditional Chinese medicine and proprietary Chinese medicine are uniformly divided into traditional Chinese medicine manufacturing industry. According to the latest data of the Ministry of industry and information technology, the income scale of China’s traditional Chinese medicine manufacturing industry in 2020 was 619.6 billion yuan, including 441.4 billion yuan in the traditional Chinese medicine manufacturing industry and 178.2 billion yuan in the traditional Chinese medicine decoction piece processing industry.
With the enhancement of people’s health awareness and the deepening understanding of traditional Chinese medicine, the demand for traditional Chinese medicine is growing and playing a more and more important role. In recent years, the income of China’s traditional Chinese medicine processing industry has fluctuated. According to the data of the Ministry of industry and information technology, the income of China’s traditional Chinese medicine processing industry in 2020 was 178.2 billion yuan, a year-on-year decrease of 7.79%. In the future, benefiting from the popularization of health awareness of traditional Chinese medicine, the acceleration of aging and the enhancement of residents’ health awareness, the demand for traditional Chinese medicine will show an upward trend year by year.
(2) Overview of health food industry
In recent years, the health food industry in China has been highly valued by governments at all levels and supported by national industrial policies. The state has successively issued a number of policies to encourage the development and innovation of the health food industry. Industrial policies such as the catalogue of health food raw materials, nutrient supplements (2020 Edition), the guide to the labeling of warning terms for health food, and the measures for the administration of the catalogue of health food raw materials and the catalogue of health functions (Order No. 13 of the General Bureau) provide a clear and broad market prospect for the development of the health food industry, It provides a good production and operation environment for enterprises.
According to the statistics of China Business Industry Research Institute, the market scale of China’s health food industry has grown steadily, from 148.2 billion yuan in 2017 to 184.7 billion yuan in 2020, with an average annual compound growth rate of 7.75%. According to China’s economic development and industry development trend, it is estimated that the market scale of China’s health food industry will exceed 200 billion yuan in 2022. As of May 2021, the National Bureau of statistics has responded to questions about the current situation and trend of China’s population aging. The data show that China’s population aged 60 and over has exceeded 264 million, accounting for 18.70%. The elderly population in six provinces in China has exceeded 10 million. China is already in an aging environment. Due to China’s large population base, the corresponding aging population is huge. As the human function will gradually decline with the growth of age, the elderly’s pursuit of health is becoming more and more urgent. The potential market capacity of health products brought by China’s aging population is large. (I) main business of the company
The company is a national high-tech enterprise specializing in the breeding, cultivation, processing and sales of rare Chinese herbal medicines such as Ganoderma lucidum, Dendrobium candidum and saffron. Its core products mainly include Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) brand Ganoderma lucidum spore powder (wall breaking), Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) brand wall breaking Ganoderma lucidum spore powder, Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) brand wall breaking Ganoderma lucidum spore powder particles, Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) brand wall breaking Ganoderma lucidum spore powder tablets, Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) brand Tiepi Fengdou particles Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) brand iron sheet Fengdou Ganoderma lucidum extract, etc.
The company always adheres to the business objective of “innovating modern biotechnology, cultivating rare and rare medicinal materials, developing the essence of Chinese medicine and serving the people’s health and longevity”, focusing on the core business of the processing and health food of precious Chinese herbal medicines, such as Ganoderma lucidum and Dendrobium candidum, constantly improving the “whole industry chain” business mode, optimizing the industrial layout, expanding the development space, relying on the core competitive advantage of Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) brand. Comprehensively enhance the comprehensive strength of enterprises and realize the rise from regional leading enterprises to national organic national pharmaceutical brand enterprises.
(II) main business model of the company
The company’s main products are Ganoderma lucidum spore powder (broken wall), broken wall Ganoderma lucidum spore powder, broken wall Ganoderma lucidum spore powder particles, broken wall Ganoderma lucidum spore powder tablets, iron Fengdou particles and iron Fengdou Ganoderma lucidum extract. Its main business model is as follows:
Raw material supply, production and sales
Retail of processed Chinese Herbal Pieces
Planting and direct selling of self-produced traditional Chinese medicine breeding base
Mode Internet
Ganoderma lucidum spore
Dendrobium officinale, Dendrobium officinale, etc
Outsourcing (providing seed sources and technical guidance) distribution of time-honored pharmacies
Model chain drugstore
General procurement mode (no seed source is provided) deep processing health food shopping malls and supermarkets
1. Raw material supply mode
The production raw materials of the company are mainly Ganoderma lucidum spore powder (raw material), fresh Dendrobium candidum, dried Dendrobium candidum and other traditional Chinese medicinal materials, which are mainly produced by the base and purchased from abroad. In addition, the company also purchases Ganoderma lucidum rods provided by the company to cultivate Ganoderma lucidum and produce Ganoderma lucidum spore powder by itself.
(1) Base self production mode
The self production mode of the base refers to that the company leases land and employs employees to cultivate and manage Ganoderma lucidum and Dendrobium candidum in strict accordance with the planting standards and requirements of the enterprise, so as to form the company’s own planting base. When Ganoderma lucidum and Dendrobium candidum reach the picking state, the company will pick them according to the production plan and use them as raw materials.
Under this mode, the company can effectively control the quality and safety of raw materials from the source and ensure the stable supply of raw materials, but the initial investment is large and the recovery period is long. At present, the company has established standardized planting bases of traditional Chinese medicine in Baimu Township and Yuyuan township of Wuyi, which are mainly used for planting traditional Chinese medicine such as Ganoderma lucidum, Dendrobium candidum, saffron, Hangzhou White Chrysanthemum and trefoil green.
(2) Outsourcing mode
There are two outsourcing modes: one is the cooperative planting mode, that is, the company signs a contract with farmers and farmers’ professional cooperatives to provide strains, seedlings and technical guidance free of charge. When the Ganoderma lucidum spore powder (raw material), Ganoderma lucidum rod, fresh Dendrobium candidum and Dendrobium candidum dry products produced by farmers or farmers’ professional cooperatives are accepted, the company will buy back all of them at the agreed price agreed in advance in the contract. The second is the general procurement mode, that is, the company directly purchases Ganoderma lucidum spore powder (raw material), fresh Dendrobium candidum, other traditional Chinese medicine, matrix and other raw materials that meet the company’s quality standards from farmers, farmers’ professional cooperatives or other legal institutions at the market price. The outsourcing mode of the company is mainly cooperative planting mode.
Under the cooperative planting mode and general procurement mode, the Ganoderma lucidum spore powder (raw material) provided by farmers’ professional cooperatives and farmers to the company has not been processed or broken, and the wall breaking of Ganoderma lucidum spore powder (raw material) is completed by the company.
2. Production mode
The production process of the company is as follows:
Material supply of annual improved seed breeding plan
Market forecast and sales plan + year+
degree
+The annual production plan of the base organizes the production quality inspection of the whole industrial chain and the warehousing of products
yield
meter
Row
Company development planning ++
Annual factory production plan and equipment maintenance
At the end of each year, the production technology center formulates the next year’s improved seed breeding plan, base production plan and factory production plan according to the company’s five-year development strategy and the market forecast and sales plan provided by the marketing center. After being approved by the general manager, the company’s current year’s production plan is formed, and the production technology center combines the base greenhouse construction, base planting cycle, equipment operation, raw material and finished product inventory Production cycle and other factors, form a monthly production plan, and arrange production after being approved by the deputy general manager in charge of production.
3. Sales model
The company implements a sales model dominated by distribution and supplemented by direct sales. Direct selling mode master
